

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://www.fdi-lab.org) on Mar 31, 2025

T24

RRID:CVCL_0554

Type: Cell Line

Proper Citation

(RRID:CVCL_0554)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0554

Proper Citation: (RRID:CVCL_0554)

Sex: Female

Defining Citation: [PMID:77569](#), [PMID:571047](#), [PMID:651066](#), [PMID:663932](#), [PMID:833871](#), [PMID:864752](#), [PMID:870558](#), [PMID:2607719](#), [PMID:3518877](#), [PMID:3708594](#), [PMID:4133950](#), [PMID:6220172](#), [PMID:6244232](#), [PMID:6823318](#), [PMID:6826254](#), [PMID:7017212](#), [PMID:7185004](#), [PMID:7787250](#), [PMID:8873383](#), [PMID:9247707](#), [PMID:9290701](#), [PMID:9850064](#), [PMID:11416159](#), [PMID:11921286](#), [PMID:12068308](#), [PMID:15846775](#), [PMID:16885334](#), [PMID:19105184](#), [PMID:19375735](#), [PMID:22460905](#), [PMID:23401075](#), [PMID:24018021](#), [PMID:24035680](#), [PMID:24367658](#), [PMID:24376083](#), [PMID:24459064](#), [PMID:25997541](#), [PMID:26055179](#), [PMID:26589293](#), [PMID:26972028](#), [PMID:27141528](#), [PMID:27270441](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29732388](#), [PMID:30193179](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Proteome analysis by 2D-DE/MS., Omics: Protein expression by reverse-phase protein arrays., Omics: GPI-anchored proteins analysis by proteomics., Omics: Exosome proteome analysis., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Omics: CNV analysis., Omics: Array-based CGH., Population: Caucasian; Swedish., Part of: UBC-40 urothelial bladder cancer cell line index., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: BLA-40 bladder carcinoma cell line panel.

Category: Cancer cell line

Name: T24

Synonyms: T-24, T 24

Cross References: BTO:BTO_0001345, CLO:CLO_0009235, CLO:CLO_0009245, CLO:CLO_0050843, CLO:CLO_0050844, EFO:EFO_0002864, MCCL:MCC:0000455, CLDB:cl4452, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-4, BCRC:60062, BCRJ:0231, BioGRID_ORCS_Cell_line:360, BioSample:SAMN03472744, BioSample:SAMN03473324, BioSample:SAMN10987918, cancercellines:CVCL_0554, CCLV:CCLV-RIE 0062, CCRID:1101HUM-PUMC000295, CCRID:3101HUMSCSP536, CCRID:3101HUMTCHu55, CCRID:4201HUM-CCTCC00078, CCRID:5301HUM-KCB92027YJ, CCTCC:GDC0078, Cell_Model_Passport:SIDM01184, ChEMBL-Cells:ChEMBL3307700, ChEMBL-Targets:ChEMBL614774, CLS:300352, Cosmic:716174, Cosmic:724812, Cosmic:755400, Cosmic:845561, Cosmic:846275, Cosmic:925832, Cosmic:928817, Cosmic:943742, Cosmic:1001664, Cosmic:1016880, Cosmic:1046673, Cosmic:1285130, Cosmic:1285985, Cosmic:1302355, Cosmic:1927302, Cosmic:1938698, Cosmic:2037960, Cosmic:2050465, Cosmic:2057459, Cosmic:2444230, Cosmic:2686118, Cosmic:2700999, Cosmic-CLP:724812, DepMap:ACH-000018, DSMZ:ACC-376, DSMZCellDive:ACC-376, EGA:EGAS00001000978, GDSC:724812, GEO:GSM136233, GEO:GSM492493, GEO:GSM887683, GEO:GSM888775, GEO:GSM1374940, GEO:GSM1574571, GEO:GSM1670520, IARC_TP53:3722, IARC_TP53:21131, IARC_TP53:30178, JCRB:JCRB0711, KCB:KCB 92027YJ, KCLB:30004, LiGeA:CCL_255, LINCS_HMS:50048, LINCS_LDP:LCL-1709, Lonza:862, PharmacDB:T24_1554_2019, PRIDE:PXD003105, PRIDE:PXD030304, Progenetix:CVCL_0554, PubChem_Cell_line:CVCL_0554, RCB:RCB0431, RCB:RCB2536, TKG:TKG 0443, TOKU-E:3252, Ubigene:YC-C044, Wikidata:Q54971454

ID: CVCL_0554

Record Creation Time: 20250131T202742+0000

Record Last Update: 20250131T204722+0000

Ratings and Alerts

No rating or validation information has been found for T24.

No alerts have been found for T24.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 58 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](https://www.fdi-lab.com/sci-crunch.org).

Reinhold A, et al. (2025) Ionizing radiation and photodynamic therapy lead to multimodal tumor cell death, synergistic cytotoxicity and immune cell invasion in human bladder cancer organoids. *Photodiagnosis and photodynamic therapy*, 51, 104459.

Li W, et al. (2024) UBE2C-induced crosstalk between mono- and polyubiquitination of SNAT2 promotes lymphatic metastasis in bladder cancer. *The Journal of clinical investigation*, 134(13).

Kawahara I, et al. (2024) Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine- and cisplatin-resistant models. *Molecular oncology*, 18(9), 2196.

Schwartz L, et al. (2024) Insulin receptor signaling engages bladder urothelial defenses that limit urinary tract infection. *Cell reports*, 43(4), 114007.

Tian S, et al. (2024) Design, performance, processing, and validation of a pooled CRISPR perturbation screen for bacterial toxins. *Nature protocols*.

Yan Y, et al. (2024) IMP2 drives chemoresistance by repressing cisplatin-induced apoptosis and ferroptosis via activation of IPO4 and SLC7A11 under hypoxia in bladder cancer. *Cancer cell international*, 24(1), 386.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Zhao Y, et al. (2024) SUMOylation-Driven mRNA Circularization Enhances Translation and Promotes Lymphatic Metastasis of Bladder Cancer. *Cancer research*, 84(3), 434.

Zhang H, et al. (2024) Role of Forkhead Box P3 in IFN γ -Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition. *Cancer research communications*, 4(8), 2228.

Chen H, et al. (2024) circKDM1A suppresses bladder cancer progression by sponging miR-889-3p/CPEB3 and stabilizing p53 mRNA. *iScience*, 27(4), 109624.

Hernández-Prat A, et al. (2024) Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitors. *Molecular oncology*.

Dressler FF, et al. (2024) Proteomic analysis of the urothelial cancer landscape. *Nature communications*, 15(1), 4513.

Li Y, et al. (2023) An HGF-dependent positive feedback loop between bladder cancer cells and fibroblasts mediates lymphangiogenesis and lymphatic metastasis. *Cancer*

communications (London, England), 43(12), 1289.

Yao Z, et al. (2023) Proteogenomics of different urothelial bladder cancer stages reveals distinct molecular features for papillary cancer and carcinoma in situ. *Nature communications*, 14(1), 5670.

Jin H, et al. (2023) Lipid raft protein flotillin-1 is important for the interaction between SOS1 and H-Ras/K-Ras, leading to Ras activation. *International journal of cancer*, 152(9), 1933.

Kim B, et al. (2023) Quantitative proteomics identifies TUBB6 as a biomarker of muscle-invasion and poor prognosis in bladder cancer. *International journal of cancer*, 152(2), 320.

Klümper N, et al. (2023) PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma. *Oncoimmunology*, 12(1), 2267744.

Uehara T, et al. (2023) Translocation of nuclear chromatin distribution to the periphery reflects dephosphorylated threonine-821/826 of the retinoblastoma protein (pRb) in T24 cells treated with *Bacillus Calmette-Guérin*. *Cytotechnology*, 75(1), 49.

Xie R, et al. (2023) NAT10 Drives Cisplatin Chemoresistance by Enhancing ac4C-Associated DNA Repair in Bladder Cancer. *Cancer research*, 83(10), 1666.

Zhang X, et al. (2023) Cancer-keeper genes as therapeutic targets. *iScience*, 26(8), 107296.